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Methods: In this prospective observational study prospectively
observed events were only included. The Rosendaal linear inter-
polation methodology was used for calculation of TTR.Based on
individual TTR all patients were categorized into 4 quartiles, 1st
quartile (<51%), 2nd quartile(51-58.15%), 3rdquartile(58.15-
66.55%), highest quartile (>66.55%) all events distribution was
compared with quartiles.
Results: Total of 256 patients were followed for 461 pt years. Pa-
tients in 1st quartile,had significantly higher risk of PVT(OR-22.78,
P¼0.0028),TEE(OR-9, P¼0.041),and TBE(OR-26, P¼0.0017)than
highest quartile, whereas no significant difference for CE, MBE
between 1stquartile and highest quartile. Patients in 2nd quartile
had significantly higher risk for only TBE (OR-9, p<0.041) than
highest quartile.PVT, TEE, TBE risk is significantly higher in lowest
quartiles(<51%) whereas only risk of TBE is higher in 2nd quarti-
le.There is no significant difference between 3rd and 4th quartiles
for any event.
Conclusion: In patients with mechanical valve on LOAC therapy
risk of events like PVT,TEE,TBE, correlates with low
TTR<51%,whereas only TBE correlates with low TTR<58.15% thus
optimal TTR for them is ABOVE 58%.Thus TTR can be used to
predict risk of events like PVT,TEE,TBE in mechanical heart valve
patients.
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Background: Right-sided valve abnormalities are less common
than their left-sided counterparts. Furthermore, whilst organic
rheumatic involvement of the tricuspid valve is not uncommon, it
receives less attention than left-sided heart valves & frequently
missed on routine clinical examination. Our aim was to study the
prevalence of tricuspid and pulmonary valve involvement in
rheumatic heart disease.
Methods: We prospectively studied 713 patients of rheumatic
valvular heart disease from January 2011 to june 2014.Tricuspid
and pulmonary valve was examined echocardiographically for
stenosis and regurgitation.The severity was graded according to
ASE guidelines.
Results: Among 713 patients of rheumatic heart disease stud-
ied,mitral valve involment was seen in 77% patients,aortic valve
involvement in 56% patients while both mitral and aortic
involvement was seen in 49% of patients.Among these pa-
tients,122 (17.11%) had organic tricuspid valve disease.In this 71
(58.19%) were females and 51 (41.8%) weremales.Out of these total
122 patients, 78 (63.93%) had isolated tricuspid regurgitation, 44
(36.06%) had tricuspid stenosis with or without tricuspid regurgi-
tation. 6 (4.91%) patients had isolated tricuspid valve stenosis.
Functional tricuspid regurgitation was found in 406 (56.94)%
patients.From total number of patients with organic TR ,19
(15.57%) had mild;68 (55.73 %) had moderate and 35 (28.68%) had
severe tricuspid regurgitation.There was no single patient with
organic pulmonary valve involvement.
Conclusions: We conclude that Rheumatic tricuspid valve disease
is not uncommon among patients with rheumatic heart disease,
but attracts less attention and might, therefore, be overlooked.
Echocardiography is the most common diagnostic tool and is
must for further management.Pulmonary valve involvement is
very rare.Appropriate treatment of the tricuspid valve disease,-
even when secondary to left heart diseases,may improve long
term outcome.
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Background: Obstructive thrombosed prosthetic heart valve
(OTPHV) is a serious complication of mechanical heart valve
replacement. There are no generally accepted criteria for man-
agement of these patients with obstructed prosthetic valves. In
the present study we aimed to study the 30 day outcome of pa-
tients who presentedwith obstructed prostheticmechanical heart
valves to a tertiary care hospital.
Methods: A total of 22 consecutive patients presenting with 27
instances of PHVT were included in the study between and 2013
and 2014. The diagnosis of PHVT was established mainly by
echocardiography by increased mean gradients across the pros-
thetic valve. The fibrinolytic agents used were streptokinase (STK)
in 16 PHVT episodes and urokinase (UK) in 2 cases, 8 cases were
directly referred to redo valve replacement surgery and 4 cases
were referred to surgery after failed fibrinolytic therapy. One pa-
tient had 4 episodes of PHVT and shown improvement with
fibrinolysis each time, and two patients had 2 episodes of PHVT.
The efficacy of Fibrinolytic therapy or surgery was assessed from
hemodynamic parameters derived from echocardiographic ex-
aminations as well as on clinical grounds and 30 day outcomes
were analyzed.
Results: Among the 22 cases of PHVT 18 cases were involving the
mitral valves only 4 cases were aortic mechanical prosthetic heart
valves. Death occurred in 6 cases of 18 cases (33%) who were
treated with fibrinolytic therapy with in 1 week of admission to
the hospital and 4 PHVT episodes has shown only partial
improvement and they were referred to the surgery. Death
occurred in 3 cases of 12 cases (25%) who underwent redo pros-
thetic valve replacement .There were 4 documented embolic ep-
isodes occurred in the fibrinolytic group . No hemorrhagic
episodes were documented.
Conclusions: These results indicate that redo surgical prosthetic
valve replacement has a reducedmortality and complications rate
in comparison to fibrinolytic therapy in patients with obstructed
prosthetic heart valves.
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Background: Although coronary artery disease (CAD) is the most
common cause cardiovascular mortality worldwide but rheu-
matic heart disease (RHD) still continues to be one of themajor CV
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